非小細胞肺がん(NSCLC)治療薬の世界市場:市場、企業、研究開発展望...市場調査レポートについてご紹介

【英文タイトル】Non-Small Cell Lung Cancer Drugs: Market, Companies and R&D Outlook 2015-2025

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Report Overview
1.1 Non-Small Cell Lung Cancer (NSCLC) Overview
1.2 Why You Should Read this Report
1.3 How this Report Delivers
1.4 Main Questions Answered by this Report
1.5 Who is this Report for?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQ)
1.8 Some Associated Reports
1.9 About Visiongain

2. Introduction to NSCLC and its Treatment
2.1 Lung Cancer is the Most Common Cancer, and NSCLC Accounts for 85%-90% of All Cases
2.2 The Three Main Histological Sub-Types of NSCLC
2.3 Genetic Mutations Allow for Targeted Therapies
2.4 Staging of NSCLC
2.5 Treatment Protocols by Stage
2.5.1 Stage 1 or 2
2.5.2 Stage 3
2.5.3 Stage 4: First Line-Therapy
2.5.3.1 Standard Chemotherapy Used to be the Only Treatment Option
2.5.3.2 Newer Therapies offers Improved Treatment Outcomes
2.5.3.3 Summary of First-Line Therapy Options: Un-Met Need in Squamous Patient Population
2.5.4 Maintenance Therapy
2.5.5 Second-Line and Third-Line Therapy

3. Leading NSCLC Drugs, 2015-2025
3.1 Alimta (pemetrexed) by Eli Lilly – The Leading NSCLC Therapy
3.1.1 Mechanism of Action
3.1.2 Three out of its Four FDA-Approved Indications are for NSCLC
3.1.3 Patent Expiries
3.1.3.1 ‘Method-Of-Use’ Vitamin Dosage Regimen Patent – Alimta’s Saviour from Generic Competition?
3.1.4 NICE Rejects Alimta for Maintenance Therapy
3.1.5 Total Alimta Revenues, 2010-2014
3.1.6 Alimta for NSCLC, 2014
3.1.7 Alimta for NSCLC Forecast, 2015-2025
3.2 Avastin (bevacizumab) – Roche’s Cancer Behemoth is a Leading Presence in NSCLC
3.2.1 Mechanism of Action
3.2.2 Multiple Approved Indications, but NSCLC was one of the First
3.2.3 Growing Discontent with Avastin in NSCLC – Is it Cost-Effective?
3.2.4 Total Avastin Revenues, 2010-2014
3.2.5 Avastin for NSCLC Forecast, 2015-2025
3.3 Tarceva (erlotinib) by Roche
3.3.1 Mechanism of Action
3.3.2 Three of Four Indications are for NSCLC
3.3.3 NICE Changes Mind on Tarceva – and then Changes it Back Again
3.3.4 Total Tarceva Revenues, 2010-2014
3.3.5 Tarceva for NSCLC Forecast, 2015-2025
3.4 Iressa (gefitinib) by AstraZeneca
3.4.1 Iressa Finally Returns to the Crucial US Market after Four Year Departure
3.4.2 Iressa NSCLC Revenues, 2010-2014
3.4.3 Iressa for NSCLC Forecast, 2015-2025
3.5 Gilotrif (afatinib) by Boehringer Ingelheim
3.5.1 Newcomer to the Market Rounds out the Trio of Currently Approved EGFR Inhibitors
3.5.2 Gilotrif Displays Significant Survival Benefit over Tarceva in Squamous Setting
3.5.3 Gilotrif for NSCLC Forecast, 2015-2025
3.6 Xalkori (crizotinib) by Pfizer
3.6.1 Mechanism of Action
3.6.2 The First Approved ALK Inhibitor
3.6.3 Co-Promotion with Merck KGaA, and has Treated Over 8,000 Patients
3.6.4 Xalkori NSCLC Revenues, 2012-2014
3.6.5 Xalkori for NSCLC Forecast, 2015-2025
3.7 Abraxane (paclitaxel Protein-Bound) by Celgene
3.7.1 Mechanism of Action
3.7.2 Relatively Recent Approval for NSCLC Indication
3.7.3 Finally Approved for NSCLC in the EU
3.7.4 Total Abraxane Revenues, 2010-2014
3.7.5 Abraxane for NSCLC Forecast, 2015-2025
3.8 Taxotere (docetaxel) by Sanofi
3.8.1 Mechanism of Action and Approved Indications
3.8.2 Sanofi Unable to Prevent Generics, Despite Appeal
3.8.3 Total Taxotere Revenues, 2010-2014
3.8.4 Taxotere for NSCLC Forecast, 2015-2025
3.9 Cyramza (ramucirumab) by Eli Lilly
3.9.1 Mechanism of Action
3.9.2 Many Approvals in Quick Succession
3.9.3 Cyramza for NSCLC Forecast, 2015-2025
3.10 Gemzar (gemcitabine) by Eli Lilly
3.11 Zykadia (ceritinib) by Novartis
3.11.1 Mechanism of Action and Recent Approval
3.11.2 Zykadia for NSCLC Forecast, 2015-2025
3.12 Opdivo (nivolumab) by Bristol-Myers Squibb
3.12.1 Mechanism of Action – Works With the Immune System to Fight Cancers
3.12.2 Swift Approvals through FDA Priority Review Programmes
3.12.3 Good News and Bad News for NSCLC from CheckMate Trials
3.12.4 Opdivo for NSCLC Forecast, 2015-2025

4. NSCLC R&D Pipeline, 2015-2025
4.1 Alecensa (alectinib) by Roche
4.1.1 Japan Becomes First Country to Approve and Launch Alectinib
4.1.2 Roche is Inching Closer Towards the All-Important US Approval
4.1.3 Four Ongoing Clinical Trials involving Alectinib in NSCLC
4.1.4 Japanese Revenues and Future Outlook
4.2 Vargatef (nintedanib) by Boehringer Ingelheim
4.2.1 EU Becomes First Region to Approve Vargatef
4.2.2 NICE has a Change of Heart on Vargatef
4.2.3 Ongoing Clinical Trials Involving Vargatef in NSCLC
4.3 AZD9291 by AstraZeneca
4.3.1 Regulatory Filings in the US and EU, Expected Times for Filings in Japan and China
4.3.2 Collaboration with Roche to Develop Companion Diagnostic
4.3.3 Positive Preliminary Results Presented at ASCO 2015
4.3.4 Ongoing Clinical Trials Involving AZD9291 in NSCLC
4.4 Rociletinib (CO-1686) by Clovis Oncology
4.4.1 In a Race to Approval Against AZD9291
4.4.2 Results So Far Have not Distinguished it Enough from Main Rival
4.4.3 Four Ongoing Clinical Trials Involving Rociletinib in NSCLC
4.5 Keytruda (pembrolizumab) by Merck (MSD)
4.5.1 Has Been Approved for Melanoma, NSCLC is one of the Next Major Targets
4.5.2 Ongoing Clinical Trials Involving Keytruda in NSCLC
4.6 Ganetespib (STA-9090) by Synta Pharmaceuticals
4.6.1 Ganetespib Mechanism of Action
4.6.2 Three Ongoing Clinical Trials Involving Ganetespib in NSCLC
4.7 Halaven (eribulin) by Eisai
4.7.1 Halaven Mechanism of Action
4.7.2 Clinical Trials Involving Halaven in NSCLC
4.8 Necitumumab by Eli Lilly
4.8.1 Phase 3 Results Show Modest Benefits and Worrying Adverse Event Profile
4.8.2 Eli Lilly has Filed for Approval in US and EU, and Verdict is Likely to be Positive, Despite Reservations
4.8.3 Ongoing Clinical Trials Involving Necitumumab in NSCLC
4.9 Atezolizumab (MPDL3280A) by Roche
4.9.1 Mechanism of Action
4.9.2 Atezolizumab Doubles Likelihood of Survival in Certain Subset of Patients
4.9.3 Six Ongoing Clinical Trials Involving Atezolizumab in NSCLC

5. Global NSCLC Market, 2015-2025
5.1 The Global NSCLC Market Forecast, 2015-2025
5.2 What Factors will Drive Growth in the Global NSCLC Market?
5.3 Growing Ageing Population
5.4 The Identification of Biomarkers for Targeted Therapies
5.5 Dynamic and Lucrative Sector with Strong Pipeline
5.6 Satisfying the Large Un-Met Need that is Treatment for Squamous Patients
5.7 What Factors will Restrain Growth in the Global NSCLC Market?
5.8 Patent Expiries and Generic Erosion will be the Main Detriment to the Market
5.9 New Therapies That Reportedly Offer Only Modest Benefits Over Existing Treatments
5.10 Declining Healthcare Budgets lead to Cost Pressures, and Resistance to Therapies is another Issue
5.11 SWOT Analysis of the Global NSCLC Market

6. Leading Therapeutic Segments and National Markets within the Global NSCLC Market
6.1 Therapeutic Composition of the Market in 2015 Compared to 2025
6.1.1 Therapeutic Segments Forecast, 2015-2025
6.1.2 Chemotherapy Segment Forecast, 2015-2025
6.1.3 EGFR and ALK Inhibitors Segment Forecast, 2015-2025
6.1.4 VEGF / VEGFR Inhibitors Segment Forecast, 2015-2025
6.1.5 Immunotherapy Segment Forecast, 2015-2025
6.2 Leading National Markets for NSCLC
6.2.1 Regional Composition of the Global Market in 2015, Compared to 2025
6.2.2 Leading Regional Markets for NSCLC Forecast, 2015-2025
6.2.3 US NSCLC Market, 2015-2025
6.2.3.1 Experiencing Some Changes, but Will Retain Dominance Throughout Forecast Period
6.2.3.2 US NSCLC Market Forecast, 2015-2025
6.2.4 EU5 NSCLC Market, 2015-2025
6.2.4.1 German NSCLC Market: Leader in EU, but Facing Big Reforms
6.2.4.2 German NSCLC Market Forecast, 2015-2025
6.2.4.3 French NSCLC Market: Strong National Healthcare System, Despite Economic Woes
6.2.4.4 French NSCLC Market Forecast, 2015-2025
6.2.4.5 Italian NSCLC Market
6.2.4.6 Italian NSCLC Market Forecast, 2015-2025
6.2.4.7 UK NSCLC Market: Pricing is a Key Issue, Providing Restraints to Revenues
6.2.4.8 UK NSCLC Market Forecast, 2015-2025
6.2.4.9 Spanish NSCLC Market
6.2.4.10 Spanish NSCLC Market Forecast, 2015-2025
6.2.5 Japanese NSCLC Market
6.2.5.1 Expansion of the Generics Market is a Key Factor
6.2.5.2 Japanese NSCLC Market Forecast, 2015-2025
6.2.6 BRIC NSCLC Market, 2015-2025
6.2.6.1 China NSCLC Market: Rapid Growth Will Make it one of the Major Global Players
6.2.6.2 China NSCLC Market Forecast, 2015-2025
6.2.6.3 Brazilian NSCLC Market: Taken Great Strides Forward with Healthcare
6.2.6.4 Brazilian NSCLC Market Forecast, 2015-2025
6.2.6.5 Russian NSCLC Market: Punches Below its Weight
6.2.6.6 Russian NSCLC Market Forecast, 2015-2025
6.2.6.7 Indian NSCLC Market: Generics are King
6.2.6.8 Indian NSCLC Market Forecast, 2015-2025

7. Research Interview
7.1 Interview with Novartis
7.1.1 On the Need for More than one ALK Inhibitor on the Market
7.1.2 Main Trends and Opportunities for NSCLC
7.1.3 The Present and the Future

8. Conclusions from Our Research and Analysis
8.1 How Will Revenues Change over the Forecast Period?
8.2 How will the Therapeutic Composition of the Market Change over the Forecast Period?
8.3 How Will the National Composition of the Global Market Change Over the Forecast Period?
8.4 Concluding Remarks


【レポート販売概要】

■ タイトル:非小細胞肺がん(NSCLC)治療薬の世界市場:市場、企業、研究開発展望
■ 英文:Non-Small Cell Lung Cancer Drugs: Market, Companies and R&D Outlook 2015-2025
■ 発行日:2015年10月
■ 調査会社:visiongain
■ 商品コード:VGAIN5112511
■ 調査対象地域:グローバル
  • 世界の公衆安全におけるモバイルブロードバンド市場
    Wireless broadband plays a significant role in improving ability of public safety personnel to efficiently communicate and obtain critical information in the form of real-time videos, images, and other forms of data. The creation of a state-of-the-art nationwide wireless broadband network for public safety purpose ensures that the public safety benefits of wireless broadband are available througho …
  • Acute Ischemic Stroke:市場分析及び予測(~2017)
    OpportunityAnalyzer: Acute Ischemic Stroke - Opportunity Analysis and Forecasts to 2017 Summary The acute ischemic stroke (AIS) market is poised for major changes during the forecast window out to 2017. Given the impending patent expiry of Activase/Actilyse, in 2015 and 2016 in the US and 5EU respectively, the current standard of care for AIS patients is expected to lose its leading position. From …
  • 世界のスキンケア製品市場動向:企業M&A(2014年5月)
    Synopsis The report provides a review of the mergers and acquisitions (M&As), partnering deals, and agreements entered into by companies active in the global skincare market during May 2014. Summary Using this report, dealmakers will effectively gain an insight into deal activity of the global skincare market throughout the month. Additionally, the report provides an overview of all the partnering …
  • 2014 Leading Diagnostic Imaging Market Players : Analogic, Esaote, GE, Hitachi, Hologic, Philips, Shimadzu, Siemens, Toshiba
    The companies analyzed in this report include Analogic, Esaote, GE, Hitachi, Hologic, Philips, Shimadzu, Siemens, and Toshiba.  The report presents insightful strategic assessments, including:Business, new product development, and marketing strategies.Anticipated acquisitions, joint ventures, and divestitures.The U.S. and international sales force size in major geographic regions.Selling opti …
  • Petrominerales Ltd.:石油・ガスの開発・生産動向及びコスト分析- Q2, 2013
    Petrominerales Ltd. Oil & Gas Exploration and Production Operations and Cost Analysis - Q2, 2013 Summary Petrominerales Ltd. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for …
  • 脊椎管狭窄症治療のグローバル臨床試験動向(2014年下半期)
    Spinal Stenosis Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Spinal Stenosis Global Clinical Trials Review, H2, 2014" provides data on the Spinal Stenosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Spinal Stenosis. It includes an overview of the trial numbers and their recruitment status as …
  • 医療レポート:Idiopathic Pulmonary Fibrosis-疫学予測(~2022)
    EpiCast Report: Idiopathic Pulmonary Fibrosis - Epidemiology Forecast to 2022 Summary Idiopathic pulmonary fibrosis (IPF) is a chronic, fibrosing interstitial pneumonia of unknown cause that occurs primarily in older adults and is associated with a histologic and/or radiologic pattern of usual interstitial pneumonia (NHLBI, 2011; Raghu et al., 2011). As a fatal disease that falls under the umbrell …
  • SDS(Software Defined Storage)の世界市場:ストレージハイパーバイザー、ストレージ仮想化ソフトウェア、コントロールプレーン、データサービス
    The software defined storage market has gained major importance due to the explosion of data center services. The software defined storage includes storage hypervisors, storage virtualization software, control plane, and data services. The enterprises are continuously trying to run data centers in an efficient and cost-effective way. In order to use less energy and infrastructure from their end, S …
  • マルチチャネル・キャンペーン管理ソリューションの世界市場
    Increase in data through different communication channels such as mobile, call centers, emails and websites has driven the multichannel campaign management (MCM) market. The rise in customer expectations for real-time view about cross-channel advertisement and one-to-one personalized experiences with brands drive the demand for innovative marketing campaigns. Digital marketing solutions providers …
  • 世界の心臓補助装置開発動向:医療機器パイプライン分析2015
    Cardiac Assist Devices - Medical Devices Pipeline Assessment, 2015 Summary GlobalData's Medical Devices sector report, “Cardiac Assist Devices - Medical Devices Pipeline Assessment, 2015" provides an overview of Cardiac Assist Devices currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of de …
  • エルシニア検査の世界市場2015
    The report presents a detailed analysis of the Yersinia diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Yersinia definition, epidemiology and etiology are reviewed. The report provides the 5- and 10-year test volume and sales forecasts by country for the following market segments:     - Hospitals      …
  • パーキンソン病:グローバル医薬品市場予測及び分析(~2022)
    PharmaPoint: Parkinson’s Disease - Global Drug Forecast and Market Analysis to 2022 Summary Parkinson’s disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson’s disease may affect individuals of any age but prevalence is increased with age and it is most common in …
  • グラノーラバーの世界市場2017-2021
    About Granola Bars Maintaining a healthy lifestyle and a healthy diet is a top priority among consumers today. However, besides health benefits, consumers also look for good taste when purchasing food products. Thus, granola bars fit the requirements of consumers. The portability and filling capacity of these bars are the other reasons behind their growing popularity. Technavio’s analysts forecast …
  • ナトリウム・リグニンスルホン酸エステルの世界市場
    Sodium Ligninsulfonate (CAS 8061-51-6) Market Research Report 2013 presents comprehensive data on sodium ligninsulfonate markets globally and regionally (Europe, Asia, North America etc.) The Sodium Ligninsulfonate (CAS 8061-51-6) Market Research Report 2013 includes sodium ligninsulfonate description, covers its application areas and related patterns. It overviews sodium ligninsulfonate market, n …
  • 可変周波数駆動装置(VFD)の世界市場2015-2022
    According to Stratistics MRC, the Global Variable Frequency Drives (VFD) market is accounted for $18.12 billion in 2015 and is expected to reach $34.36 billion by 2022 growing at a CAGR of 9.5% during the forecast period. Increase in demand, price of the electricity, enlarging usage of variable frequency drives and following the best energy efficiency standards in manufacturing VFD are the major f …
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。